Organic Active Ingredients TRIZ Cases

A high-bulk-density cariprazine capsule blend improves flowability, limits agglomeration, and supports uniform large-scale filling.

Cardiosphere-derived cells and exosomes target dystrophic skeletal muscle to reduce fibrosis and inflammation while restoring dystrophin.

A three-component LNP uses a steroid-cationic lipid to simplify mRNA delivery while improving stability, transfection, and aerosol inhalation use.

Novel glutaminyl cyclase inhibitors improve metabolic stability and lower hydrophobicity while suppressing aberrant immune cell chemotaxis.

Small-molecule eIF2B modulators restore translation initiation under p-eIF2α stress, attenuating ISR while limiting broader translation effects.

Sequential hyaluronic acid then mesenchymal stem cell injection improves cartilage damage treatment while avoiding high-concentration drawbacks.

Crystalline free base and fumarate salt forms improve ATM inhibitor stability, processing, and blood-brain barrier penetration.

An intranasal adrenalin and doxepin composition improves bioavailability and rapid onset for shock treatment while supporting dosage reliability.

A biodegradable naltrexone implant cuts swelling and pain at the implant site while sustaining drug release without removal.

Furoindazole compounds tune substituent patterns to selectively inhibit GPR84 and improve treatment of inflammatory, autoimmune, and metabolic disorders.

Direct lung delivery of inhaled itraconazole helps treat idiopathic pulmonary fibrosis with lower doses, improved bioavailability, and fewer side effects.

Specific purine A2aR antagonists expand treatment coverage across neurological, fibrotic, and cancer-related disorders with stronger therapeutic benefit.

Small molecules such as CD04872SC block Spike-ACE2 binding to prevent SARS-CoV-2 variant entry with minimal cytotoxicity.

Selective pyrimidine ring CDK2 inhibitors address cyclin E-driven resistance that limits the duration of CDK4/6 cancer therapy.

Ion exchange extraction isolates caffeoylquinic acids from stevia or yerba mate to cut off-tastes and enable edible use.

Specific A3-B3 CEACAM5 binding avoids CEACAM cross-reactivity and enables internalizing antibody conjugates to kill tumor cells.

Hydrophilic-hydrophobic oligonucleotide conjugates self-assemble into nanoparticles that improve hair root cell delivery and suppress androgen receptor expression.

A pyrazole or pyrazoline vasodilator scavenges ROS, blocks peroxynitrite formation, and preserves nitric oxide vessel dilation.

An LLP2A-bisphosphonate conjugate treats osteonecrosis by increasing vascular density, limiting cell death, and helping prevent bone collapse.

NQO1 substrate compounds raise NAD+ and shift macrophages toward oxidative phosphorylation to suppress inflammatory cytokines.

Selective Bcl-xL inhibitor derivatives use tuned BH3-mimetic features to trigger cancer cell apoptosis while managing platelet-related effects.

Defined MSA and sulfate crystal forms improve Compound I stability, solubility, and pH resistance for reproducible isolation and purification.

A multi-compound antiviral composition blocks replication, entry, and release while reducing cytokine storm risk and preserving cellular integrity.

Palovarotene lowers HBsAg, HBeAg, HBV DNA, and cccDNA, addressing rebound risk left by replication-only hepatitis B therapies.

Selective phenyl amino pyrimidine compounds address the JAK2 specificity bottleneck while enabling treatment of cancer, inflammatory, and vascular diseases.

Acetylated serum albumin helps preserve vascular endothelium during prolonged EVLP, reducing edema and vascular resistance.

Hydrophobic methylene violet derivatives improve cellular uptake and mitochondrial protection while reducing cytotoxicity in antioxidant therapy.

Citric acid or saccharin turns deliquescent 1,2,4-oxadiazole derivatives into stable solids that are easier to handle, store, and manufacture.

A solid-state upadacitinib form enables oral treatment of rheumatoid arthritis and giant cell arteritis while reducing corticosteroid dependence and flares.

Targeted R1-R4 aminosterol modifications extend pharmacokinetic half-life and potency while preserving biological activity for disease treatment.

Ultra-high-dose-rate FLASH radiation paired with therapeutic agents boosts tumor killing while limiting normal tissue toxicity and preserving immune response.

Modified GLP-1R agonists resist DPP-4 degradation to enable oral dosing and prolonged activity for obesity, NASH, and Type 2 diabetes.

Biofilm-forming probiotics in prebiotic microspheres help restore the intestinal mucosal barrier and prevent antibiotic-induced dysbiosis.

Bile acids activate GPR39 through zinc-independent or allosteric pathways, enabling agonist development for GPR39-related disorders.

Shifting cellular metabolism from fatty acid oxidation to glucose oxidation helps reduce fibrotic tissue and preserve organ function.

Targeted or systemic antifibrinolytic delivery restrains fibrinolytic activity after concussion to limit brain tissue damage.

A multi-ingredient natural composition improves glomerular filtration, lowers waste markers, and may delay hemodialysis in CKD care.

Modified 2-methoxyestradiol compounds inhibit fibrotic tissue formation to treat or prevent liver and pulmonary fibrosis.

Baseline and monitored plasma arginine levels help select and adjust arginine deprivation therapy to delay resistance and improve survival.

GalNAc-LNPs improve targeted RNA delivery in receptor-deficient cells by combining lipid self-assembly with hepatocyte-targeting conjugates.

Engineered exosomes deliver nucleic acids and antibodies to tumor-associated macrophages, improving selective M2-to-M1 repolarization for cancer therapy.

Small-molecule USP1 inhibitors expand treatment options by selectively suppressing USP1 activity in cancers linked to DNA repair defects.

Reduced-solubility EFdA diester suspensions extend plasma exposure and sustain HIV suppression for weeks to months after parenteral dosing.

A stealth liposome controls PGI2 agonist release to improve disease-site accumulation, sustain efficacy, and reduce systemic side effects.

Selective IKZF2 degraders lower Treg activity at tumor sites to boost anti-tumor immunity while reducing systemic toxicity.

Localized inhalation of gold compounds targets viral entry and lung inflammation while reducing systemic side effects.

Multiple-dose castanospermine analog regimens cut RSV viral load and inflammation even when treatment is not limited to early exposure.

A sculptured chitosan film supports prostatic neurovascular bundle repair while reducing inflammation, infection risk, incontinence, and erectile dysfunction.

Cannabinoids adsorbed in porous solid carriers improve oral solubility, release stability, and bioavailability for more consistent dosing.

Molecular profiling of RTEL1 variants guides inhibitor use to improve pan-cancer treatment precision while avoiding unnecessary exposure.

Bacteroides enzymes convert salicin into saligenin, enabling microbiome-based IBD treatment through host immunoregulatory modulation.

Stable RAD1901-2HCl polymorphs resist humidity-driven conversion, preserving consistent drug delivery and therapeutic effectiveness in cancer treatment.

Heteroaryl substitutions improve MIF inhibitor solubility, metabolic stability, and pharmacokinetic behavior while preserving inhibitory activity.

A bound lysozyme-chitosan complex inhibits Acanthamoeba adhesion and proliferation, offering a safer alternative to biguanide-based treatments.

Phosphonium salt chromenones improve pharmacological and physicochemical properties while preserving anticancer treatment efficacy.

A reconstituted Trientine liquid dosage form improves swallowing ease and dosing accuracy while maintaining chemical and physical stability.

RNAi agents silence PRNP RNA to lower prion protein levels and slow neurodegenerative disease progression with fewer symptoms.

Mutation-specific gRNAs and AAV9 vectors improve PLN-R14Del editing while sparing wild-type PLN and easing Cas9 delivery limits.

Fused imidazole compounds inhibit osteoclast differentiation and bone resorption to reduce bone loss while maintaining bone density.

By stopping CYP2C9 inhibitors before Compound I dosing, this case reduces drug exposure and adverse events in JAK-responsive treatment.

A biodegradable in situ leuprolide depot sustains ovarian suppression and lowers estradiol during endocrine therapy for HR-positive breast cancer.

Epicardial-derived factors such as hypoglycosylated FSTL1 help repair ischemic heart tissue by boosting cardiomyocyte survival, vascularization, and limiting fibrosis.

A defined crystalline Form C balances stability, solubility, and manufacturability for oral NMDA modulator solid dosage forms.

An enteric NMN capsule protects against gastric acid, then releases in the intestine to improve flora balance and support mucosal barrier function.

A quinolone composition for IBS-D aims to improve symptom control while avoiding the side effects seen with existing IBS treatments.

A 5% minoxidil and low-dose finasteride foam or liniment speeds alopecia treatment while improving efficacy and reducing irritation.

Polymer-coated praziquantel granules and co-granulated moxidectin improve taste masking, stability, and bioavailability in veterinary tablets.

Combining N-acetylcysteine with nicotinamide riboside helps address oxidative stress and mitochondrial dysfunction linked to brain energy deficits.

A PDE10 inhibitor offers an alternative to neuroleptics by reducing Tourette tics and related neurobehavioral disorders with fewer side effects.

Novel uracil derivatives inhibit coronavirus 3CL protease to block viral replication while supporting broader strain coverage through scaffold variation.

Modified dsRNA with phosphorothioate linkages and nucleotide changes improves PRNP mRNA silencing for prion disease treatment.

Buffer exchange to pH 4.5-6.9 before lyophilization helps nucleic-acid lipid nanoparticles retain storage stability and gene delivery after rehydration.

Macrocyclic FKBP51 binders use targeted substituents to preserve affinity and selectivity while lowering molecular weight and lipophilicity.

Non-hormonal agents modulate ovarian cell polypeptides to suppress ovulation while reducing side-effects and dosing inconvenience.

Controlled hydroxypropyl beta-cyclodextrin purification removes propylene glycol, endotoxin, and unsubstituted species for chronic CNS dosing.

Dual IRAK1/IRAK4 inhibition counters compensatory IRAK1 activation and improves sustained treatment response in AML and MDS.

A 1-aminomethylisochroman compound series broadens CNS treatment beyond positive symptoms to target cognitive impairment and apathy.

Co-loaded STING and TLR4 agonists in nanoparticles activate APC and NK responses to attack dormant tumor cells and limit metastasis.

Small-molecule SAE inhibitors block overactive sumoylation, restore type 1 interferon expression, and support cancer therapy development.

Small molecules tuned to enhance SIRT6 deacylase activity help lower LDL and triglycerides, improve glucose tolerance, and inhibit fibrosis.

Selective CDK2 inhibitor compounds use active-site binding to regulate cell-cycle progression and prevent aberrant DNA replication in cancer.

A modified-release oral minoxidil formulation sustains serum exposure for hair regrowth while reducing peak concentrations tied to adverse effects.

Selective CDK7 inhibitors improve kinase specificity and suppress resistant cancer cell proliferation, including triple-negative breast cancer.

Novel pyrrolo[1,2-b]pyridazine derivatives balance IRAK4 potency with solubility, stability, and lower hERG off-target risk.

Antisense oligomers promote skipping of SETD5 NMD exons to raise productive mRNA and functional protein expression in deficiency-related disease.

A thick biodegradable membrane reservoir enables zero-order subcutaneous drug release for 60+ days with a flat PK profile and minimal tail.

Novel dihydroisoxazole compounds inhibit Mycobacterium tuberculosis while reducing mitochondrial-linked myelosuppression risk.

Synthetic ddhNTP derivatives clarify P2 receptor activation while enabling host defense modulation, tissue regeneration, and anti-infective use.

Novel Formula I compounds extend HIV dosing intervals while maintaining efficacy against drug-resistant variants.

Nebulized liposomal amikacin improves lung delivery and symptom relief in newly diagnosed MAC infection while reducing systemic toxicity.

Using PEG lipids at 87%+ purity in LNP formulations reduces immune recognition and blood clearance, enabling repeated dosing with maintained activity.

pH control, antioxidants, and metal chelators suppress ESA and D-epinephrine formation to extend epinephrine shelf life.

HPβCD depletes cellular cholesterol to reverse EMT, improve cancer therapy sensitivity, and reduce metastasis with fewer side effects.

Targeted pyrrolopyrimidine scaffolds vary substituents to improve ITK inhibition and expand treatment options for inflammatory disease.

Selective HER2 inhibitor zongertinib penetrates the blood-brain barrier to shrink CNS metastases while maintaining manageable safety.

Nebulized low molecular weight heparin targets cancer therapy lung damage to reduce inflammation, fibrosis, and coagulation without systemic bleeding risk.

Irreversible mutant EGFR inhibitors use pyrrolopyridine derivatives to address exon20 insertion activity and poor brain permeability in cancer treatment.

A defined HSPC, memory T cell, and Treg graft composition improves engraftment while limiting naïve T cells to reduce GVHD.

A Formula 1 compound enhances neuronal transmission and long-term potentiation to improve memory, cognition, and learning decline.

A segmented trigger and blocking mechanism lowers firing force while preventing accidental injection and component binding in compact injectors.